Evidence for cross-hemispheric preconditioning in experimental Parkinson's disease

Brain Struct Funct. 2018 Apr;223(3):1255-1273. doi: 10.1007/s00429-017-1552-6. Epub 2017 Nov 4.

Abstract

Dopamine loss and motor deficits in Parkinson's disease typically commence unilaterally and remain asymmetric for many years, raising the possibility that endogenous defenses slow the cross-hemispheric transmission of pathology. It is well-established that the biological response to subtoxic stress prepares cells to survive subsequent toxic challenges, a phenomenon known as preconditioning, tolerance, or stress adaptation. Here we demonstrate that unilateral striatal infusions of the oxidative toxicant 6-hydroxydopamine (6-OHDA) precondition the contralateral nigrostriatal pathway against the toxicity of a second 6-OHDA infusion in the opposite hemisphere. 6-OHDA-induced loss of dopaminergic terminals in the contralateral striatum was ablated by cross-hemispheric preconditioning, as shown by two independent markers of the dopaminergic phenotype, each measured by two blinded observers. Similarly, loss of dopaminergic somata in the contralateral substantia nigra was also abolished, according to two blinded measurements. Motor asymmetries in floor landings, forelimb contacts with a wall, and spontaneous turning behavior were consistent with these histological observations. Unilateral 6-OHDA infusions increased phosphorylation of the kinase ERK2 and expression of the antioxidant enzyme CuZn superoxide dismutase in both striata, consistent with our previous mechanistic work showing that these two proteins mediate preconditioning in dopaminergic cells. These findings support the existence of cross-hemispheric preconditioning in Parkinson's disease and suggest that dopaminergic neurons mount impressive natural defenses, despite their reputation as being vulnerable to oxidative injury. If these results generalize to humans, Parkinson's pathology may progress slowly and asymmetrically because exposure to a disease-precipitating insult induces bilateral upregulation of endogenous defenses and elicits cross-hemispheric preconditioning.

Keywords: Adaptation; Basal ganglia; Dopamine; Hormesis; Neurodegeneration; Parkinson’s disease; Preconditioning; Tolerance.

MeSH terms

  • Adrenergic Agents / toxicity
  • Animals
  • Anthraquinones / metabolism
  • Corpus Striatum / metabolism
  • Corpus Striatum / pathology*
  • Disease Models, Animal
  • Dopamine / metabolism
  • Dopaminergic Neurons / physiology
  • Functional Laterality / drug effects
  • Functional Laterality / physiology*
  • Male
  • Mice
  • Mitogen-Activated Protein Kinase 1 / metabolism
  • Oxidopamine / toxicity
  • Parkinsonian Disorders / chemically induced
  • Parkinsonian Disorders / pathology*
  • Parkinsonian Disorders / physiopathology*
  • Substantia Nigra / metabolism
  • Substantia Nigra / pathology*
  • Superoxide Dismutase / metabolism
  • Tyrosine 3-Monooxygenase / metabolism

Substances

  • 1,5-bis((2-(methylamino)ethyl)amino)-4,8-dihydroxyanthracene-9,10-dione
  • Adrenergic Agents
  • Anthraquinones
  • Oxidopamine
  • Tyrosine 3-Monooxygenase
  • Superoxide Dismutase
  • Mapk1 protein, mouse
  • Mitogen-Activated Protein Kinase 1
  • Dopamine